Clinical Trials Browser

Subcutaneous panniculitis-like T-cell lymphoma, Immunoblastic Lymphadenopathy, Lymphoma, Follicular, Mycosis Fungoides, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic, Enteropathy-Associated T-Cell Lymphoma

NCT04541108 2026-05-22

Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies

Phase EARLY_PHASE1 Active not recruiting

15 enrolled

DermatologicHead & NeckLymphoidSarcoma

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Lymphoma, Melanoma, Sarcoma

NCT02965716 2026-05-20

Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma

Phase 2 Active not recruiting

43 enrolled 18 charts

Dermatologic

Melanoma

NCT05537740 2026-05-20

A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors

Phase 1 Active not recruiting

129 enrolled

BreastDermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Recurrence, Triple Negative Breast Neoplasms

NCT05034536 2026-05-18

PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma

Phase 2 Active not recruiting

36 enrolled

Dermatologic

Melanoma

NCT03645928 2026-05-15

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

Phase 2 Terminated

225 enrolled

DermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT07160335 2026-05-15

A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors

Phase 1 Recruiting

174 enrolled

DermatologicGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

Clinical Trials

BEPCOME-MB

MK-3475-G21

Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)

MK-3475-051

Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma

Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma

A Study of ASP1012 in Adults With Solid Tumors

SUPRAME

Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

KEYMAKER-U02

A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III Melanoma

A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors

Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas